WPI has 10 other research projects going on
I have started to wonder, for those who are XMRV positive that will probably be your cause of CFS symptoms.
But what about those who are XMRV negative, are WPI going to continue to search for what is wrong with those patients.
Because we could be left with a frightening situation, a huge amount of people that maybe given a psychiatric lable.
I have something called POTS - postural orthostatic tachycardia syndrome. I have had this since I got CFS, no one knows what causes POTS.
If I am XMRV negative, I'm not happy to have a psychiatric lable to explain my physical suffering, so I guess I would simply just have POTS and not CFS or XMRV.
What I'm trying to say is, will WPI continue to fight for the rest of us, if and when they get the XMRV/CFS connection approved.
Will they continue there research to explain the rest of us ?
1) Being XMRV negative by blood test may not mean you don't have it. Sometimes the immune system is so damaged not even antibodies can be found. Sometimes it can only be found in other tissue.
2) WPI is investigating other aspects of CFS: (All the more reason to donate NOW, if you can.)
Current Research Program
Study Title and Description Collaborators
Role of Chronic Inflammatory and Immune Stimulation by Active Herpesvirus Infection in the Development of Immune Dysfunction in CFS
Studies of immune abnormalities in this CFS cohort will involve phenotypic analysis of NK, DC, and T cell populations. States of activation and differentiation will be studied to determine whether the cells are immune activators or suppressors due to response to infection. The goal is to understand the imbalance in the immune system that leads to unregulated virus expression. Francis Ruscetti, PhD, NCI
Dennis Taub, PhD, NIA
(INIP Research Award)
Novel Viruses/Co-infections in Subgroups of CFS
A Virus DNA Microarray (Virochip) was used to screen a cohort of CFS with Immunological defects and increased incidence of Mantle cell lymphoma (MCL). Francis Ruscetti, PhD, Cancer Inflammation Program, NCI
Role of the Interferon/RNaseL Antiviral Pathway in CFS
The goal of this study is to characterize defects in the Interferon/RNaseL antiviral pathway which result in viral persistence. Robert Silverman, PhD, Cleveland Clinic
Role of Inflammatory Cytokines and Chemokines in CFS
The purpose of this study is to identify and develop the serum biomarker patterns of cytokine and chemokines, which correlate with clinical disease and can be used to monitor intervention. Dennis D. Taub, PhD, NIA
Host Susceptibility in CFS
The goal of this study is to elucidate genetic factors of susceptibility and the dysregulation of the host defense system in order to develop biomarkers for diagnostic development and thus predict response to immune modulating therapy and vaccines. Jonathan R. Kerr, MD, PhD, St. Georges University, London UK
Mary Carrington, PhD, NCI
Mike Dean, PhD, NCI
Enumeration and Function of Natural Killer (NK) Cells in CFS
The purpose of this project is to develop improved NK diagnostic tests for both the number and function of NK cells. Doug Redelman, PhD, UNR, Dept. of Microbiology & Immunology
Epidemiologic Evaluation of Lymphoma and Cancer Incidence in Nevada CFS Cohort
The goal of this study is to determine if a possible cancer cluster exists in the cohort of Nevada CFS patients. Paul Levine, MD, George Washington University
Study of Clonal T Cell Receptor-gamma Rearrangements in Nevada CFS Cohort
The purpose of this study is to determine the significance of clonal T cell receptor-gamma rearrangements in the pathogenesis of CFS. Dorothy Hudig, PhD, UNR, Dept. of Microbiology & Immunology
Development of a Whole Genome Transcriptome Assay for HHV6
The goal is to develop a whole genome transcriptome assay for HHV6 and a sub array for HHV6A specific detection to be used as a diagnostic tool or research tool to understand the viral life cycle in disease. Rachel Bagni, PhD, Applied Technology Program, NCI
HHV6 Latency in CFS
The goal of this study is to understand the role of HHV6A latency in bone marrow hematopoietic stem cells in the pathogenesis of CFS. Stephen St. Joer, PhD
Marianna Bego, PhD, UNR, Dept. of Microbiology & Immunology